http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
자궁내막증에 의한 통증에 대한 GnRH agonist와 Levonorgestrel 함유 자궁내장치 (Mirena(R)) 병합 치료의 유용성에 관한 고찰
조문경 ( Moon Kyoung Cho ),김철홍 ( Cheol Hong Kim ),조혜연 ( Hye Yeon Cho ),오성택 ( Sung Tack Oh ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.3
Objective: The purpose of this study was to evaluate the effects of levonorgestrel-releasing intrauterine system (Mirena(R)) combination to GnRH (gonadotropin releasing hormone) agonist treatment on chronic pelvic pain of endometriosis, hypoestrogenic symptoms. Methods: One hundred twenty eight patients who were diagnosed as endometriosis, were divided into endometriosis without adenomyosis group (n=88) and endometriosis with adenomyosis group (n=40). In 57 of 88 patients who had only endometriosis without adenomyosis, only GnRH agonist for 6 months was injected monthly (Group A). In the other 31 of 88 patients, Mirena(R) was inserted and GnRH agonist for 6 months was injected monthly (Group B). In 12 of 40 patients who had endometriosis and adenomyosis, only GnRH agonist for 6 months was injected monthly (Group C). In the other 28 of 40 patients, Mirena(R) was inserted and GnRH agonist for 6 months was injected monthly (Group D). The degree of pelvic pain, dysmenorrhe, and hypoestrogenic symptoms of each groups were observed and compared. Results: The decreased pain rates of Group B and D were significantly higher than Group A and C (p<0.01), and decreased pain rates of Group D were significantly higher than Group B (p<0.05). The incidence of hot flush, depression and insomnia of 4 groups were not significantly different. Conclusions: Although Mirena(R) combination to GnRH agonist treatment cannot prevent the hypoestrogeic symptoms, Mirena(R) combination increases the treatment effect for pain of endometriosis. Especially, this effect is the more if adenomyosis is combined to endometriosis.
조문경 ( Moon Kyoung Cho ),박형무 ( Hyoung Moo Park ) 대한폐경학회 2011 대한폐경학회지 Vol.17 No.3
연구목적: 2010년 국내에서 판매된 호르몬 제제의 규모를 조사하여 최근 판매량과 비교해 보고, WHI 연구에 대한 재평가들이 국내 호르몬 사용에 미친 영향을 살펴본다. 연구재료 및 방법: 국내에서 판매된 호르몬 제제의 품목과 비용은 Intercontinental Marketing Services (IMS)의 2010년 약제 통계자료를 근거로 산출하였다. 에스트로겐 또는 에스트로겐/프로게스토겐 복합제제와 티볼론 제제로 나누어 조사하여, 2002년 이후의 사용량과 비교하였다. 또한, 2010년에 사용된 호르몬 제제의 종류별 비율 및 사용 빈도를 추정해 보았다. 결과: 50세 이상의 여성 중 4.5%가 2010년 한 해 동안 호르몬 제제를 복용한 것으로 추정되었다. 제제별 사용비율은 에스트로겐 또는 에스트로겐/프로게스토겐 복합제제가 60%, 티볼론이 40%를 차지하였다. 2010년 호르몬 제제의 총 사용량은 381억원으로 전년도에 비해 7% 상승하였다. 에스트로겐 또는 에스트로겐/프로게스토겐 복합제제는 9%, 티볼론은 4% 상승하였다. 결론: 2002년 이후 호르몬 제제의 사용량은 크게 감소하였다가, WHI 연구 결과의 재분석, 의사들의 인식변화, 티볼론 사용량의 증가로 2007년부터 조금씩 증가하여 2010년까지 증가 추세가 유지되고 있다. 호르몬 제제 처방 시에는 약제의 득과 실을 환자에게 충분히 설명하고, 약제 투여 전 자세한 병력 청취 및 신체 검사 등을 통해 환자에게 가장 적절한 호르몬 제제를 선택하도록 해야 한다. Objectives: To analyze the domestic consumption of postmenopausal hormonal medicine in the year 2010 and compare it with those since 2002. Methods: Data from Intercontinental Marketing Services were used to analyze the consumption of hormonal medicine in the year 2010. Total hormonal medicines consisted of estrogen (ET), estrogen+progestogen (EPT), and Tibolone. We compared the respective consumption of hormonal medicines in the year 2010 with those since 2002. The percentage and frequency of usage of ET, ET/EPT, and tibolone in the year 2010 were also estimated. Results: We found that 4.5% of women over 50 years of age had taken the postmenopausal hormonal medicine in the year 2010. The usage rate of each medicine showed 60% for ET/EPT compound, and 40% for Tibolone. The usage of postmenopausal hormonal medicine in 2010 increased by 7% compared to the previous year reaching 3.81 billion Korean won. There was 9% increase in the use of ET/EPT compound, and 4% increase in Tibolone. Conclusion: The total consumption of postmenopausal hormonal medicine was markedly decreased between 2002 and 2007. Since 2007, however, it has been steadily increasing from 3.01 billion to more than 3.81 billion Korea won in 2010, which maybe due to the reappraisal of the WHI study results, the change of doctor`s recognition, and the increased consumption of Tibolone. When initiating postmenopausal hormone replacement therapy, the risk-benefit of hormonal therapy should be thoroughly explored. (J Korean Soc Menopause 2011;17:150-154)
조문경(Moon-Kyoung Cho),구본비(Bon-Bi Koo),김소희(So-Hee Kim) 한국색채학회 2015 한국색채학회 학술대회 Vol.2015 No.11
인간과 환경과의 관계를 새롭게 인식하면서 나타난 공간 환경 개선을 위한 디자인은 지역 주민의 삶을 향상시키고 지역의 정체성을 되찾아 활력을 줄 수 있는 가능성을 가진다. 본 연구는 최근 변화하는 농어촌의 다양한 사회적 요구에 대응하여 지역의 특색을 담은 공간 환경개선에 관한 방안을 찾아가는 기초적 작업이다. 농어촌 환경 개선을 위한 정책과 방향을 통해 우선적으로 환경개선을 위한 공간 대상을 선정 분류하고 이러한 대상에 대한 환경개선 방법의 범주를 제시한다. 이것은 농어촌의 구조개선과 지역 주민의 삶의 질을 개선시키는 방향으로 농어촌 경관의 획일화와 기능 저하를 극복할 수 있다. 본 연구에서는 농어촌 환경개선의 대상과 방법을 제시하여 보다 쾌적한 농어촌 환경을 조성하고자 한다.
만삭전 조기양막파열 임부에서 정맥혈장내 지질과산화도와 단백산화도의 증가
조문경 ( Moon Kyoung Cho ),김윤하 ( Yoon Ha Kim ),김철홍 ( Cheol Hong Kim ),김기민 ( Ki Min Kim ),안봉환 ( Bong Whan Ahn ),양성렬 ( Sung Yeul Yang ),김종운 ( Jong Woon Kim ),송태복 ( Tae Bok Song ) 대한산부인과학회 2007 Obstetrics & Gynecology Science Vol.50 No.4
Objective: This study was performed to investigate the lipid peroxide levels and the protein carbonyl groups content in the venous plasma of pregnant women with preterm premature rupture of membranes (PPROM), non-pregnant, and normal pregnant women. Methods: Samples of venous blood were obtained from women with non pregnancy (n=20), normal pregnancy between 25 and 37 weeks gestation (n=20), and PPROM before 37 completed weeks gestation (n=20). Lipid peroxide levels in the venous plasma of women of each group were measured by thiobarbituric acid reaction. The basal, amoxacillin and moxalactam-induced protein carbonyl contents in the venous plasma of women of each group were determined by the 2,4-dinitrophenylhydrazine (DNPH) method. Results: 1. Lipid peroxide levels in the venous plasma of PPROM was significantly higher than that of non-pregnant and normal pregnant women (5.66±0.43 vs. 3.78±0.24 vs. 3.56±0.30 nmol/mg protein, p<0.01). 2. Protein carbonyl levels in the venous plasma of PPROM was also significantly higher than that of non-pregnant and normal pregnant women (8.23±0.54 vs. 6.39±0.23 vs. 6.54±0.24 nmol/mg protein, p<0.01). 3. Protein carbonyls formation by moxalactam in the venous plasma of PPROM was significantly higher than that of non-pregnant and normal pregnant women (11.73±0.59 vs. 10.06±0.26 vs. 10.10±0.22 nmol/mg protein, p<0.05). 4. There was no significant difference in protein carbonyls formation by amoxacillin of the venous plasma of pregnant women with PPROM, non-pregnant, and normal pregnant women (5.63±0.41 vs. 5.81±0.43 vs. 5.81±0.39 nmol/mg protein, p>0.05). 5. There were ignificant positive correlations between lipid peroxide and moxalactam-induced protein carbonyls levels of the venous plasma (p<0.05). There were no significant positive correlations between lipid peroxide and amoxacillin-induced protein carbonyls levels of the venous plasma. Conclusion: In the venous plasma of pregnant women with PPROM, the lipid peroxidation and the protein carbonyl formation were increased. And moxalactam-induced protein carbonyl levels were increased in PPROM. These results suggest that oxydative stress was increased in pregnant women with PPROM.